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Abstract: Chitosan (CS) iron oxide magnetic nanoparticles (MNPs) were coated with phytic acid 
(PTA) to form phytic acid-chitosan-iron oxide nanocomposite (PTA-CS-MNP). The obtained 
nanocomposite and nanocarrier were characterized by powder X-ray diffraction, Fourier trans-
form infrared spectroscopy, vibrating sample magnetometry, transmission electron microscopy, 
and thermogravimetric and differential thermogravimetric analyses. Fourier transform infrared 
spectra and thermal analysis of MNPs and PTA-CS-MNP nanocomposite confirmed the binding 
of CS on the surface of MNPs and the loading of PTA in the PTA-CS-MNP nanocomposite. The 
coating process enhanced the thermal stability of the anticancer nanocomposite obtained. X-ray 
diffraction results showed that the MNPs and PTA-CS-MNP nanocomposite are pure magnetite. 
Drug loading was estimated using ultraviolet-visible spectroscopy and showing a 12.9% in 
the designed nanocomposite. Magnetization curves demonstrated that the synthesized MNPs 
and nanocomposite were superparamagnetic with saturation magnetizations of 53.25 emu/g 
and 42.15 emu/g, respectively. The release study showed that around 86% and 93% of PTA 
from PTA-CS-MNP nanocomposite could be released within 127 and 56 hours by a phosphate 
buffer solution at pH 7.4 and 4.8, respectively, in a sustained manner and governed by pseudo-
second order kinetic model. The cytotoxicity of the compounds on HT-29 colon cancer cells 
was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The 
HT-29 cell line was more sensitive against PTA-CS-MNP nanocomposite than PTA alone. 
No cytotoxic effect was observed on normal cells (3T3 fibroblast cells). This result indicates 
that PTA-CS-MNP nanocomposite can inhibit the proliferation of colon cancer cells without 
causing any harm to normal cell.
Keywords: nanocomposite, drug delivery, chitosan, phytic acid, HT-29 cell line, controlled 
release
Introduction
Nanotechnology has incredible potential for revolutionizing the medical world by devel-
oping personalized medicine both for diagnosis and therapy. Nanomedicine (nanosized 
therapeutics and imaging agents) has exhibited a strong growth in nanodrugs where 
designed ingenious biocompatible nanocomposites for drug delivery purposes. These 
nanocomposites are widely used as nanodelivery systems that enhance the biodistribution 
of drugs and selectively target diseased tissues while protecting healthy tissues.1,2
Various nanocarriers including liposomes,3–6 cell-based nanocarriers,7 polymers,8 carbon 
materials,9,10 dendrimers,11 and inorganic nanoparticles12,13 have been employed for gene and 
drug delivery systems, which have shown efficacy both in vitro and in vivo. Recently, much 
attention has been devoted to polymer-based nanoparticles (typically chitosan [CS]-iron 
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oxide nanoparticles) as novel cellular delivery vectors in cancer 
therapy because of their excellent properties such as high encap-
sulation efficiency, sustained release properties, effective and 
convenient routes of administration, less toxicity, endocytosis 
efficiency, surface modifying capacity, ability to differentiate 
between cancer and normal cells,14 superparamagnetic behavior 
and contrast agent, and low health care cost.15
Iron oxide magnetic nanoparticles (MNPs) with general 
formula Fe
3
O
4
 have been widely used for delivery of various 
drugs owing to some advantages: ease of preparation, 
superparamagnetic property,16–18 biocompatibility, external 
control, controllable parameters,19,20 and hypothermal 
behavior.21,22 However, these nanoparticles due to the pres-
ence of OH− groups with a large surface area to volume ratio 
and dipole–dipole attraction without any surface coating 
will be agglomerated and the size of particles will increase. 
Therefore, it is necessary to use polymers in the coating 
process to prevent the nuclear growth of iron oxide, preclude 
nanoparticles aggregation, and reduce toxic effect.23–25
CS, a natural polymer and deacetylated deriva-
tive of chitin, is most commonly used as a coating mate-
rial for nanoparticles in anticancer drug delivery systems 
because of its unique biological features including 
biocompatibility,26 anti-carcinogenicity, biodegradability, 
nontoxicity, hydrophilicity,23,27–29 and great antimicrobial 
property.30 The CS polymer reacts with iron oxide nanopar-
ticles through glycosidic bonds and improves the stability 
and chemical reactivity of nanoparticles.31
Extensive studies using CS-MNPs nanocarrier have been 
performed in recent years to enhance anticancer drug efficacy 
and reduce the side effects of the drug. For instance, Javid 
et al32 demonstrated that CS-MNPs nanoreservoir with a 
higher drug loading capacity increased the drug efficiency 
and anticancer properties of doxorubicin. The results empha-
sized that doxorubicin-CS-MNP nanocomposite showed 
a greater growth inhibitory effect on ovarian cancer cells 
(A2780 and OVCAR-3) than free drug.32
Phytic acid (PTA; C
6
H
18
O
24
P
6
) is a natural compound dis-
covered in 1903. It is the major storage form of phosphorous 
in plants and legumes, including wheat bran, corn, soy beans, 
rice bran, and nuts,33 and it is reported to possess a broad 
range of pharmaceutical properties, such as antioxidant,34,35 
chemopreventive,36,37 hepatoprotective, and anticancer prop-
erties. Many studies presented that PTA inhibited cancer cell 
growth in leukemia, prostate, breast, liver, colon, and skin 
cancers.38–40 However, this anticancer drug has very short 
plasma half-life and is released very fast.
Therefore, considering the aforementioned advan-
tages of CS-MNPs, we report here the synthesis of a new 
nanohybrid, phytic acid-chitosan-MNPs (PTA-CS-MNP). 
The objective of this research was to explore the potential 
use of CS-MNPs for the delivery of anticancer drug PTA. 
We investigated the sustained release behavior of PTA 
from CS-MNPs nanocarrier and evaluated the cytotoxic 
effects against cancer cells and normal fibroblast (3T3) 
cell lines in vitro.
Materials and methods
Materials
The chemicals in this study were of analytical grade and were 
used as received without further purification. PTA sodium 
salt from rice (molecular formula: C
6
H
18
O
24
P
6
 xNa+⋅yH
2
O; 
molecular weight: 660.04) with $90 purity and CS, deacety-
lated at 75%–85%, sodium amp salt (.98% purity; molecular 
weight: 371.4 g/mol) were acquired from Sigma-Aldrich (St 
Louis, MO, USA). Aqueous acetic acid solution (99.8%) 
was supplied by Hamburg Industries (Hamburg, Germany). 
Ferrous chloride tetrahydrate (FeCl
2
⋅4H
2
O, $99% purity) 
and ferric chloride hexahydrate (FeCl
3
⋅6H
2
O, $99% purity) 
were obtained from Merck KGaA (Darmstadt, Germany). 
Ammonia solution (25%) was purchased from Scharlau 
(Sentmenat, Barcelona, Spain). Deionized water was used 
in each experiment.
synthesis of MNPs
The MNPs were prepared by a coprecipitation method as 
previously reported.41 They were prepared by mixing solutions 
of 2.43 g of ferrous chloride tetrahydrate (FeCl
2
⋅4H
2
O), 0.99 g 
ferric chloride hexahydrate (FeCl
3
⋅6H
2
O), and 80 mL of 
deionized water in the presence of 6 mL of ammonia (25% 
by mass). The pH value of the solution was maintained 
at 10. Then the mixture was sonicated for 1 hour at room 
temperature. Finally, the precipitate was centrifuged and 
washed three times with deionized water.
synthesis of cs-MNPs
The solution of CS was prepared by dissolving 1 g of CS 
powder in 1% acetic acid solution. It was followed by 
the addition of CS solution to MNPs suspension and then 
the mixture was stirred for 18 hours at room temperature. 
The obtained mixture was centrifuged and washed three 
times with deionized water and dried at 70°C. The product 
was labeled CS-MNPs.23
synthesis of PTa-cs-MNP 
nanocomposite
The PTA-CS-MNP nanocomposite was obtained by mixing 
PTA sodium salt solution (2 g in 100 mL deionized water) 
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with a known amount of CS-MNPs. The solution was then 
kept under vigorous stirring for 24 hours. The final slurry was 
centrifuged, washed, and finally dried at 60°C oven.
characterization of PTa-cs-MNP 
nanocomposite
The magnetic property of the samples was evaluated using 
Lake Shore 7404 vibrating sample magnetometer (Lake 
Shore Cryotronics, Inc., Westerville, OH, USA). The thermal 
analyses of the materials were performed using Mettler Toledo 
thermogravimetric (TGA) and differential thermogravimetric 
(DTG) instruments with a heating rate of 10°C per minute 
at temperature 20°C–1,000°C under nitrogen atmosphere 
(N
2
 flow rate 50 mL per minute). Powder X-ray diffraction 
(PXRD) patterns were used to determine the crystal structures 
of the samples over a range of 5°–70°, using an XRD-6000 
diffractometer (Shimadzu, Tokyo, Japan) with CuKα radia-
tion (λ =1.5406 Å) at 30 kV and 30 mA. Fourier transform 
infrared (FTIR) spectra of the materials were recorded over 
a range of 400–4,000 cm−1, using a Nexus, Smart Orbit spec-
trometer (Thermo Fisher Scientific, Waltham, MA, USA) and 
KBr disk method. The ultraviolet-visible (UV-Vis) spectro-
photometer (Shimadzu 1650 series; Shimadzu) was used to 
determine the optical and controlled-release properties of PTA 
from PTA-CS-MNP nanocomposite. The mean particle size 
and size distribution were determined using a transmission 
electron microscope (Hitachi H-7100; Hitachi, Tokyo, Japan) 
at an accelerating voltage of 80 and 200 kV.
loading and release of PTa from 
PTa-cs-MNP nanocomposite
The percentage of PTA loading in PTA-CS-MNP nano-
composite was measured using UV-Vis spectrophotometer 
(Shimadzu 1650 series; Shimadzu) and calibration curve equa-
tion. Approximately 5 mg of the nanocomposite was dissolved 
in concentrated HCl/HNO
3
. In this condition 100% PTA con-
tent would be released from the nanocomposite. The amount 
of PTA released was measured by UV-Vis spectroscopy at a 
wavelength of 275 nm and using calibration curves.
PTA release profiles from the nanocomposite were deter-
mined at room temperature using 0.01 M phosphate-buffered 
saline (PBS) solution at pH 4.8 and 7.4. A total of 85 mg 
of PTA-CS-MNP nanocomposite was added to 500 mL of 
PBS medium. The cumulative amount of PTA released into 
the solution was measured at predetermined time intervals 
at λ
max
 =275 nm using a UV-Vis spectrophotometer. The 
release rate of PTA from PTA-CS-MNP nanocomposite was 
compared with that from physical mixture that contained 
PTA sodium salt, CS, and MNPs.
cytotoxicity assay of PTa-cs-MNP 
nanocomposite
HT-29 and 3T3 cells were obtained from American Type 
Culture Collection (ATCC, VA, USA), and these cells were 
cultured and plated at a density of 1×104 cells by adding 
100 μL of cell suspension to each well of a 96-well tissue 
culture plate. The plates were incubated for sufficient time to 
ensure attachment of cells. The growth rate was ~70%–80% 
confluency. The media were aspirated off and replaced with 
fresh media (100 μL) containing different concentrations of 
PTA-CS-MNP nanocomposite as well as pure compound, 
PTA (25–500 μg/mL). The treated plates were incubated at 
37°C in 5% CO
2
 for 72 hours with appropriate control. After 
incubation with the compounds, 3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution 
(5 mg/mL) in a total volume of 10 μL was added to every 
well and mixed gently with the media, which was later 
incubated for 4 hours at 37°C in 5% CO
2
. The MTT solu-
tion containing the medium was then removed carefully and 
replaced with dimethyl sulfoxide (DMSO) (100 μL per well) 
to dissolve the formazan crystals. Finally, the culture plates 
were read in a microplate reader at 570 nm. The concentra-
tion of drug needed to inhibit cell growth by 50% (IC
50
) was 
generated from the dose–response curves for each compound 
and each cell line.
Results and discussion
PXrD
Figure 1A–C illustrates the PXRD patterns of the MNPs, 
PTA-CS-MNP, and PTA sodium salt, respectively. For 
MNPs and PTA-CS-MNP nanocomposite, six characteris-
tic peaks at 2θ=30.2°, 35.5°, 43.2°, 53.5°, 57.2°, and 62.7° 
were indexed to (220), (311), (400), (422), (511), and (440), 
respectively, (JCPDS No 19-629) which are due to the cubic 
spinel structure of pure Fe
3
O
4
.42 Figure 1A and B reveals that 
the coating process did not affect the phase change of MNPs 
as there is no changes in the position of the peaks.43 However, 
the coating process resulted in a lower peak intensity and 
crystallinity of the PTA-CS-MNP nanocomposite. The mean 
grain size was calculated from XRD data by Debye-Scherrer 
equation that determines the connection between average 
particle size and peak broadening in XRD.
 
D = Kλ
β θcos  
where D is the average particle size, K is the Debye-Scherrer 
constant (0.89), λ is the X-ray wavelength (0.15406 nm), 
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β is the peak width of half-maximum, and θ is the 
diffraction angle. The mean particle size of MNPs obtained 
from this equation was ~8 nm.
FTIr spectroscopy
The FTIR spectra of MNPs, PTA-CS-MNP nanocompos-
ite, and PTA sodium salt are presented in Figure 2. The 
MNPs in Figure 2A shows an absorption peak at 569 cm−1 
that is due to the stretching of Fe-O in Fe
3
O
4
. However, 
this peak was shifted to 565 cm−1 in the PTA-CS-MNP 
nanocomposite (Figure 2B), which confirm the presence of 
MNPs in the nanocomposites.44 The broad absorption peak 
observed at 3,415 cm−1 in Figure 2A is ascribed to the O–H 
stretching. In the PTA-CS-MNP nanocomposite spectra 
(Figure 2B), the characteristic band for CS was observed 
at 1,560 cm−1, which proves that MNPs were successfully 
coated with CS.45
The FTIR spectra of PTA sodium salt shown in 
Figure 2C displays some intense, sharp absorption peaks due 
to different functional groups in the molecules. The char-
acteristic bands at 1,202 and 1,060 cm−1 can be assigned to 
the stretching vibration of P=O and P–O–C, respectively, 
and in the nanocomposite spectrum (Figure 2B), the bands 
shifted to 1,388 and 1,056 cm−1, respectively, due to 
coating process. The stretch at 511 cm−1 corresponded to 
the O–Na and O–P=O vibrations were revealed at 2,408 
and 2,920 cm−1 (Figure 2C).46 The absorption peaks of OH 
group of water molecules present in the PTA sodium salt 
appeared at 1,663 and 3,437 cm−1,46 while the peaks were 
recorded at 1,627 and 3,396 cm−1 in the nanocomposite 
spectra (Figure 2B).
Figure 3 shows the interaction between the MNPs, 
CS, and PTA. It is clear that MNPs interacted with CS 
through glycosidic bonds (Figure 3A), whereas PTA 
(Figure 3B) interacted with CS polymer through hydrogen 
bonds.47,48
Thermal analysis
The thermal behavior of PTA sodium salt, MNPs, and PTA-
CS-MNP nanocomposite was examined by TGA and DTG 
Figure 1 Powder X-ray diffraction patterns of iron oxide magnetic nanoparticles (A), 
PTa-cs-MNP nanocomposite (B), and phytic acid sodium salt (C).
Abbreviation: PTa-cs-MNP, phytic acid-chitosan-iron oxide nanocomposite.
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??????????? Figure 2 Fourier transform infrared spectra of iron oxide magnetic nanoparticles (A), PTa-cs-MNP nanocomposite (B), and phytic acid sodium salt (C).
Abbreviation: PTa-cs-MNP, phytic acid-chitosan-iron oxide nanocomposite.
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analyses (Figure 4). The PTA sodium salt thermal decom-
position (Figure 4A) showed three weight loss events. The 
first event occurred at 123°C with a weight loss of 25.9%, 
which was due to the removal of water present in the sample. 
The second weight loss of 20.6% at 205°C might be due to 
the carbonization process and dehydration that takes place 
due to the decomposition of OH groups. This third one was 
followed by the decomposition of phytate groups and the 
elimination of elemental carbon formed in the previous step 
at 309°C with a mass reduction of 41.2%.49 The TGA/DTG 
thermograms of MNPs (Figure 4B) exhibited a single-stage 
mass reduction at 44°C with a weight loss of 9.7%, which 
can be attributed to the loss of surface hydroxyl groups and 
residual water.25 For PTA-CS-MNP nanocomposite, three 
main thermal phenomena were observed (Figure 4C). The 
first weight loss of 9.6% at 62°C was related to the removal 
of surface physisorbed water molecules. The second and 
third weight loses of 23.4% and 12.1% at 242°C and 610°C, 
respectively, corresponded to the decomposition of PTA 
and CS biopolymer. The temperature region of the nano-
composite appeared to be clearly higher than that of the free 
drug due to the electrostatic attraction between the MNPs, 
CS, and PTA.
Magnetic properties
Superparamagnetism is an essential and important property 
for magnetic-targeting carriers in drug-delivery system.50 
Magnetic properties of MNPs and PTA-CS-MNP nanocom-
posite were characterized by vibrating sample magnetometer 
as a function of the magnetic field at room temperature 
(Figure 5). The saturation magnetization of MNPs was 
53.25 emu/g compared to that of PTA-CS-MNP nanocom-
posite which was 42.15 emu/g, and negligible coercivity and 
remanent magnetization were observed for both samples, 
which confirmed the superparamagnetic properties of 
the samples. The decrease in saturation magnetization of 
Figure 3 schematic representation of the interaction between iron oxide magnetic nanoparticles, chitosan (A), and phytic acid (B) in the PTa-cs-MNP nanocomposite.
Abbreviation: PTa-cs-MNP, phytic acid-chitosan-iron oxide nanocomposite.
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PTA-CS-MNPs nanocomposite could be due to the existence 
of coated materials on the surface of MNPs and electron 
exchange between CS polymer coating and Fe atoms.51–53 
This could affect surface magnetic anisotropy and enhance 
surface spins disorientation.54
Determination of average size and size 
distribution properties
Transmission electron microscopy images and size distri-
bution of pristine Fe
3
O
4
, CS-MNPs, and PTA-CS-MNP 
nanocomposite are presented in Figure 6. The images 
show that nanosized particles were successfully prepared 
using coprecipitation method, and all the samples such 
as MNPs, CS-MNPs, and PTA-CS-MNP nanocomposite 
showed roughly spherical shape (Figure 6A–C). The aver-
age size of MNPs was ~15±6 nm (Figure 6D), whereas the 
mean sizes of CS-MNPs and PTA-CS-MNP nanocom-
posite were around 12±4 nm and 8±3 nm, respectively 
( Figure 6E and F). The decrease in the size of CS-MNPs 
and PTA-CS-MNP nanocomposite after coating might be 
due to prolonged vigorous stirring at high speeds after 
adding CS and PTA.52
In vitro release study of PTa from  
PTa-cs-MNP nanocomposite
The UV-Vis absorption spectroscopy and calculations by 
calibration curve equation showed that the percentage 
Figure 4 Tga/DTg thermograms of phytic acid sodium salt (A), iron oxide magnetic nanoparticles (B), and PTa-cs-MNP nanocomposite (C).
Abbreviations: PTa-cs-MNP, phytic acid-chitosan-iron oxide nanocomposite; Tga/DTg, thermogravimetric and differential thermogravimetric analyses.
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acid-loaded chitosan-iron oxide magnetic nanoparticles (B) recorded at room 
temperature.
Abbreviation: Oe, oersted.
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Figure 6 TeM micrographs of iron oxide magnetic nanoparticles (A), chitosan-iron oxide magnetic nanoparticles (B), and PTa-cs-MNP nanocomposite (C). Particle size 
distribution of iron oxide magnetic nanoparticles (D), chitosan-iron oxide magnetic nanoparticles (E), and PTa-cs-MNP nanocomposite (F).
Abbreviations: PTa-cs-MNP, phytic acid-chitosan-iron oxide nanocomposite; TeM, transmission electron microscopy.
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Figure 7 Release profiles of phytic acid from PTA-CS-MNP nanocomposite into 
phosphate-buffered saline solution at ph 7.4 and ph 4.8. The inset shows the release 
profiles of a physical mixture of phytic acid sodium salt with chitosan and iron oxide 
nanoparticles into phosphate-buffered saline solution at ph 7.4 and ph 4.8.
Abbreviation: PTa-cs-MNP, phytic acid-chitosan-iron oxide nanocomposite.
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loading of PTA in the PTA-CS-MNP nanocomposite was 
12.9%. The release profiles of PTA from the PTA-CS-MNP 
nanocomposite and physical mixture are shown in Figure 7. 
The physical mixture of PTA sodium salt with CS and MNPs 
exposed to pH 4.8 or pH 7.4 environment shows that the 
release of PTA was fast and completed within 60 seconds 
(inset in Figure 7). However, the release rate of PTA from the 
PTA-CS-MNP nanocomposite was markedly slower than that 
from the physical mixture, indicating that the PTA-CS-MNP 
nanocomposite is a potential controlled release drug-delivery 
system. This result may be attributed to the interaction 
between the negatively charged PTA and positively charged 
protonated CS.
The release rate of PTA from PTA-CS-MNP nano-
composite is dependent on the pH of the environment; the 
release rate of PTA at pH 7.4 was remarkably lower than that 
at pH 4.8. Figure 7 shows that the percent release of drug 
from nanocomposite reached 93% within 56 hours when 
exposed to a pH environment of 4.8 and 86% by 127 hours 
at pH 7.4 PBS.
Such a difference in the release rate at pH 4.8 and 
7.4 might be due to a possible difference in the release 
mechanism of PTA from the nanocomposite. At acidic pH 
(pH 4.8), PTA-CS-MNP nanocomposite is unstable, but at 
pH 7.4, it is more stable.55,56 As a result, the release would 
occur through ion exchange between PTA anions and nega-
tive anions available on the PBS.
release kinetics of PTa from 
PTa-cs-MNP nanocomposite
A number of kinetic models describe the total release of 
PTA from PTA-CS-MNP nanocomposite. The common 
models used include pseudo-first order, pseudo-second order, 
and parabolic diffusion models. Pseudo-first order kinetic 
equation is written as follows:57
 
In q q In q kt
e t e
( )− = −
 
where q
e
 and q
t
 are the equilibrium release amount and the 
release amount at time t, respectively, and k is the constant 
of the corresponding release rate.
In pseudo-second order kinetic model, the release 
behavior of drugs from nanocomposite is described by the 
following equation:58
 
t q kq t q
t e e
= +1 2
 
By plotting t/q
t
 against t, a straight line is obtained and 
the release rate constant k, as well as q
e
, can be calculated 
using a the following relation:
 
k q intercept
e
=1 2 .
 
The parabolic diffusion kinetic model is written as 
follows:59
 
( )
.
1
0 5
−
= +−
M M
t
kt bt o
 
where M
o
 and M
t
 are the PTA content that remain in the 
nanocomposite at release time 0 and t, respectively.
Among these three kinetic models, it was found that 
the release kinetic processes of PTA from PTA-CS-MNP 
nanocomposite at pH 7.4 and 4.8 were well governed by the 
pseudo-second order model, with correlation coefficients of 
(R2) 0.9996 and 0.9980 and release rate constant (k) values 
of 1.69×10−5 and 2.86×10−5 mg/min, respectively (Figure 8 
and Table 1).
The results of kinetic model gained in this work are 
similar to the release kinetic study of the chlorogenic acid 
intercalated into the Zn/Al-LDH, Mg/Al-LDH by ion-
exchange and coprecipitation routes and ZLH58,60,61 and also 
very similar to release of protocatechuic acid from Zn/Al-
layered double hydroxide and zinc layered hydroxide.62,63
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sustained release of PTa from cs-coated MNPs
Figure 8 Fitting of the data for phytic acid release from PTA-CS-MNP nanocomposite into various solutions to the pseudo-first order, pseudo-second order kinetics and 
parabolic diffusion model for ph 7.4 (A–C) and ph 4.8 (D–F).
Abbreviation: PTa-cs-MNP, phytic acid-chitosan-iron oxide nanocomposite.
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cellular sensitivity of cells to PTa and 
PTa-cs-MNP nanocomposite
The efficacy of PTA-CS-MNP nanocomposite in suppressing 
the growth of HT29 colorectal adenocarcinoma cells was 
assessed using colorimetric assay (MTT assay). The 3T3 
normal fibroblast cells were employed as normal control 
to ensure the nontoxic nature of nanocomposite. As illus-
trated in Figure 9B, HT29 cells displayed a dose-dependent 
reduction in cell viability after 72 hours of incubation with 
nanocomposite. PTA-CS-MNP nanocomposite exerted 
a cytotoxic effect on HT29 at higher concentrations and 
showed a moderate inhibition at lower concentrations. In gen-
eral, pure compound exhibited a much lower cytotoxic effect 
on HT29 cells with a higher half maximal inhibitory concen-
tration value (IC
50
) of 188.5 μg/mL compared to PTA-CS-
MNP nanocomposite, whose IC
50
 value was 45.63 μg/mL. 
This shows that the introduction of CS-MNPs into PTA 
improved the efficacy of PTA in HT29 cells. It is apparent 
from Figure 9A that both free PTA and nanocomposite did 
not induce toxicity in 3T3 normal fibroblast cells. Both 
compounds did not affect cell viability in the tested range, 
as the survival was consistently greater than 80% or similar 
Table 1 Correlation coefficient (R2), rate constant (k), and half-life (t1/2) values obtained by fitting the release data of phytic acid from 
PTa-cs-MNP nanocomposite into phosphate-buffered saline solution at ph 4.8 and 7.4
Aqueous 
solution
Saturation 
release (%)
R2 Pseudo-second order model 
Pseudo-first 
order model 
Pseudo-second 
order model
Parabolic 
diffusion
Rate constant, 
k (mg/min)
t1/2
(min)
ph 7.4 86 0.9832 0.9996 0.8275 1.69×10−5 630
ph 4.8 93 0.9818 0.9980 0.8848 2.86×10−5 339
Abbreviation: PTa-cs-MNP, phytic acid-chitosan-iron oxide nanocomposite.
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to control. In this case, it can be suggested that PTA-CS-
MNP nanocomposite possessed good anticancer activities 
when compared with pure compound PTA and demonstrated 
selectivity between cancerous and normal cells.
Conclusion
PTA-CS-MNP nanocomposite was successfully prepared by 
coating MNPs with CS and then loading it with PTA drug. 
The loading percentage of PTA into the nanocomposite was 
12.9% and the superparamagnetic properties of PTA-CS-
MNP nanocomposite and MNPs were shown by vibrating 
sample magnetometry studies. The vibration modes of the 
coated CS to MNPs and loaded PTA, which supported 
the formation of PTA-CS-MNP nanocomposite, were 
confirmed by FTIR. The release profiles of the drug from 
nanocomposite into PBS were of sustained manner with 
total release equilibria of 86% and 93% when exposed 
to environments of pH 7.4 and 4.8 at 127 and 56 hours, 
respectively. The pseudo-second order kinetics model was 
found to be the best fitting mathematical model. Overall, 
the findings of this study suggest that PTA-CS-MNP nano-
composites possess good anticancer potential against colon 
cancer cells and do not cause any cytotoxicity to normal 
fibroblast cells. Further, cellular and molecular studies are 
needed to find out the specific cellular mechanism that 
describes the specific action of nanocomposite against colon 
cancer cells. Also, in vivo studies are to be carried out to 
prove the therapeutic potential of the present tumor-specific 
delivery system.
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